SENS

Senseonics Holdings, Inc. (SENS) | Rumor.io

Senseonics Holdings

SENS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,241

Bullish sentiment (50-day avg)91%

Price to earnings ratio-5.94

Market capitalization520.3M

Earnings per share-2.24

Dividend yield (TTM)—

Revenue (annual)35.3M

Net income (annual)-69.1M

Social

What share of all stock conversation is about SENS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.02

Sep 24

Senseonics Holdings, Inc. (SENS) is integrating its Eversense 365 CGM with other products, potentially increasing its market share.
The Eversense 365 implant is considered "game-changing" and may lead to increased adoption of SENS's products.
Analysts expect a long-term bull run for SENS, with potential resistance levels at $11.30 and $11, and a possible pullback before continuing the upward trend.

Generated by AI

Sentiment

Of the messages about SENS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	88.89% +0.89	90.58% +3.04	68.98% -11.97
Bearish	0% 0	11.11% -0.89	9.42% -3.04	31.02% +11.97

Bullish· Aug 21

The company's Q3 results could be strong, similar to the previous quarter, potentially leading to a healthy run for the stock.
A potential partnership with TNDM's pump could lead to exponential growth for Senseonics, as users prefer the company's 365 CGM product over competitors.
The stock's price action is encouraging, with insiders purchasing shares, and the company's performance is comparable to its run to $320, suggesting a potential repeat of that performance.

Bearish· May 7

The company's profitability is uncertain, with management expecting it to occur in 2027 or possibly up to 3 years later.
The recent dilution may lead to a prolonged period of price stagnation, with the stock potentially fluctuating between $5 and $6.
The company's leadership is being criticized, with some questioning CEO Tim's ability to run a business and suggesting that he may be intentionally tanking the stock for personal gain.

Generated by AI

Topics

Of the messages about SENS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	85.71%	12.76%
Earnings	0%	0%	0%	2.54%
Announcements	0%	0%	14.29%	9.39%
Analysts	0%	0%	0%	48.64%
Controversies	0%	0%	0%	0.74%
Macro	0%	0%	0%	25.92%

Earnings· Feb 11

Senseonics $SENS has updated its FY 2021 guidance to EPS and revenue guidance to $13.70 million-$13.70 million.
The company's unaudited revenue figures for the last quarter and full-year 2021 have exceeded Wall Street forecasts.
Senseonics $SENS pushed revenue expectations out a year, but this is not unusual in CovidWorld, and the FDA approval may have been priced in.

Analysts· Aug 19

HC Wainwright & Co. initiated coverage on Senseonics Holdings with a Buy rating and set a price target of $6, citing the company's potential for growth following the FDA's decision on its GCM.
Analysts at HC Wainwright & Co. are optimistic about Senseonics Holdings, with Vernon Bernardino initiating coverage with a Buy rating and a price target of $6.
The price target of $6 set by HC Wainwright & Co. represents an 83.5% upside from Senseonics Holdings' current price, according to analysts at the firm.

Announcements· Sep 4

Senseonics Holdings, Inc. (SENS) has secured a new $100 million loan agreement, refinancing existing debt and providing access to additional funding as the company achieves operational milestones.
The company plans to take over commercialization and distribution of its Eversense 365 product, integrating manufacturing and sales under one roof, which is expected to accelerate growth and improve profitability.
The move is seen as a strategic pivot, with the company now owning the commercialization path for Eversense 365, and is expected to boost growth outlook, with shares trading up 8% pre-market.

Technical Analysis· Feb 13

$SENS has been trading in a range between $1.31 and $1.41, with potential next levels at $1.50 and $1.60.
The stock needs to break above $1.32 and $1.34 to make a move higher, with potential resistance at $1.40 and $1.50.
A close above $1.32 would be a good indicator of further upward pressure, with potential for a test towards $1.60 resistance if able to remain above the 50ema on the 30min chart.

Generated by AI

Community

Of the messages about SENS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90.63%	95.31%	69.93%
Newcomers	0%	9.38%	4.69%	30.07%

Regulars· Sep 24

The Eversense 365 cgm from SENS is a game-changing implant that is highly anticipated by regulars, who believe it will be a key factor in the company's success.
The regulars are optimistic about SENS, citing a bright future ahead and a potential 10X return on investment, with some even predicting a weekly close above the 52-week high.
The majority of shorts are in the money, and regulars believe that the price will continue to rise, with a 90% chance of reaching $11, as hedge funds try to keep the price down but are ultimately unsuccessful.

Newcomers· Nov 13

The focus is on the perceived overvaluation of Senseonics Holdings, with some users expressing concerns about the risks associated with the company's CGM (Continuous Glucose Monitoring) product.
Some users are questioning the valuation of Senseonics, citing the price of $0.70 as a point of contention, while others are expressing concerns about the company's ability to meet its financial obligations.
There is a sense of urgency among the users, with many of them using emojis that convey a sense of excitement, warning, or alarm, such as 🚀, 🚩, 🔥, and 🚨, suggesting that they believe the situation with Senseonics is critical or volatile.

Generated by AI

News

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

22h agoYahoo! Finance Canada

TD Cowen reiterates Senseonics stock rating on growth drivers

1d agoInvesting.com

Update: Beta Bionics, Senseonics to Integrate Diabetes Devices; Shares Rise

(Updates with the latest stock price in the headline and last paragraph.) Beta Bionics (BBNX) rep

7d agoYahoo Finance

Beta Bionics, Senseonics Partner to Integrate Diabetes Devices

Beta Bionics (BBNX) said Tuesday it partnered with Senseonics (SENS) to integrate its iLet Bionic Pa

8d agoYahoo Finance

Beta Bionics partners with Senseonics on glucose monitoring

8d agoInvesting.com

TD Cowen reiterates Senseonics stock rating on growth drivers

8d agoInvesting.com

Also Discussed

Investors talking about SENS also mention

#	Name	Attention
1	DexCom Inc.DXCM	0%0
2	Bionano Genomics Inc.BNGO	0%0
3	Citius Pharmaceuticals, Inc.CTXR	0%0
4	Castor Maritime Inc.CTRM	0%0
5	Tandem Diabetes Care, Inc.TNDM	0%new
6	Atossa Genetics IncATOS	0%0
7	Nano Dimension Ltd. Sponsored ADRNNDM	0%+0
8	ASXC - Asensus Surgical, Inc.	——
9	Vyne Therapeutics Inc.VYNE	0%0
10	Nemaura Medical Inc.NMRD	0%new

Senseonics Holdings, Inc.

Healthcare
Medical Devices

Senseonics Holdings, Inc. is a commercial-stage medical technology company specializing in long-term, implantable continuous glucose monitoring systems for people with diabetes in the United States and internationally. The company’s Eversense product family, including Eversense, Eversense XL, Eversense E3, and Eversense 365, uses a small sensor inserted under the skin, a removable and rechargeable smart transmitter worn on the body, and a mobile application that delivers real-time glucose readings and alerts. These systems are designed to provide extended wear duration compared with traditional transcutaneous CGM devices, supporting continuous monitoring without frequent sensor replacement. Senseonics focuses on the development and manufacturing of these glucose monitoring products and distributes them through healthcare providers, distributors, and strategic commercial partners, serving the global diabetes community. Headquartered in Germantown, Maryland, Senseonics plays a specialized role in the medical technology and diabetes care market by offering differentiated implantable CGM solutions intended to support more informed and convenient day-to-day glucose management.

Website

Location

20451 Seneca Meadows Parkway

Germantown, MD, 20876-7005

United States

Social

What share of all stock conversation is about SENS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.02

Sep 24

Senseonics Holdings, Inc. (SENS) is integrating its Eversense 365 CGM with other products, potentially increasing its market share.
The Eversense 365 implant is considered "game-changing" and may lead to increased adoption of SENS's products.
Analysts expect a long-term bull run for SENS, with potential resistance levels at $11.30 and $11, and a possible pullback before continuing the upward trend.

Generated by AI

Sentiment

Of the messages about SENS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	88.89% +0.89	90.58% +3.04	68.98% -11.97
Bearish	0% 0	11.11% -0.89	9.42% -3.04	31.02% +11.97

Bullish· Aug 21

The company's Q3 results could be strong, similar to the previous quarter, potentially leading to a healthy run for the stock.
A potential partnership with TNDM's pump could lead to exponential growth for Senseonics, as users prefer the company's 365 CGM product over competitors.
The stock's price action is encouraging, with insiders purchasing shares, and the company's performance is comparable to its run to $320, suggesting a potential repeat of that performance.

Bearish· May 7

The company's profitability is uncertain, with management expecting it to occur in 2027 or possibly up to 3 years later.
The recent dilution may lead to a prolonged period of price stagnation, with the stock potentially fluctuating between $5 and $6.
The company's leadership is being criticized, with some questioning CEO Tim's ability to run a business and suggesting that he may be intentionally tanking the stock for personal gain.

Generated by AI

Topics

Of the messages about SENS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	85.71%	12.76%
Earnings	0%	0%	0%	2.54%
Announcements	0%	0%	14.29%	9.39%
Analysts	0%	0%	0%	48.64%
Controversies	0%	0%	0%	0.74%
Macro	0%	0%	0%	25.92%

Earnings· Feb 11

Senseonics $SENS has updated its FY 2021 guidance to EPS and revenue guidance to $13.70 million-$13.70 million.
The company's unaudited revenue figures for the last quarter and full-year 2021 have exceeded Wall Street forecasts.
Senseonics $SENS pushed revenue expectations out a year, but this is not unusual in CovidWorld, and the FDA approval may have been priced in.

Analysts· Aug 19

HC Wainwright & Co. initiated coverage on Senseonics Holdings with a Buy rating and set a price target of $6, citing the company's potential for growth following the FDA's decision on its GCM.
Analysts at HC Wainwright & Co. are optimistic about Senseonics Holdings, with Vernon Bernardino initiating coverage with a Buy rating and a price target of $6.
The price target of $6 set by HC Wainwright & Co. represents an 83.5% upside from Senseonics Holdings' current price, according to analysts at the firm.

Announcements· Sep 4

Senseonics Holdings, Inc. (SENS) has secured a new $100 million loan agreement, refinancing existing debt and providing access to additional funding as the company achieves operational milestones.
The company plans to take over commercialization and distribution of its Eversense 365 product, integrating manufacturing and sales under one roof, which is expected to accelerate growth and improve profitability.
The move is seen as a strategic pivot, with the company now owning the commercialization path for Eversense 365, and is expected to boost growth outlook, with shares trading up 8% pre-market.

Technical Analysis· Feb 13

$SENS has been trading in a range between $1.31 and $1.41, with potential next levels at $1.50 and $1.60.
The stock needs to break above $1.32 and $1.34 to make a move higher, with potential resistance at $1.40 and $1.50.
A close above $1.32 would be a good indicator of further upward pressure, with potential for a test towards $1.60 resistance if able to remain above the 50ema on the 30min chart.

Generated by AI

Community

Of the messages about SENS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90.63%	95.31%	69.93%
Newcomers	0%	9.38%	4.69%	30.07%

Regulars· Sep 24

The Eversense 365 cgm from SENS is a game-changing implant that is highly anticipated by regulars, who believe it will be a key factor in the company's success.
The regulars are optimistic about SENS, citing a bright future ahead and a potential 10X return on investment, with some even predicting a weekly close above the 52-week high.
The majority of shorts are in the money, and regulars believe that the price will continue to rise, with a 90% chance of reaching $11, as hedge funds try to keep the price down but are ultimately unsuccessful.

Newcomers· Nov 13

The focus is on the perceived overvaluation of Senseonics Holdings, with some users expressing concerns about the risks associated with the company's CGM (Continuous Glucose Monitoring) product.
Some users are questioning the valuation of Senseonics, citing the price of $0.70 as a point of contention, while others are expressing concerns about the company's ability to meet its financial obligations.
There is a sense of urgency among the users, with many of them using emojis that convey a sense of excitement, warning, or alarm, such as 🚀, 🚩, 🔥, and 🚨, suggesting that they believe the situation with Senseonics is critical or volatile.

Generated by AI

Senseonics Holdings

Social

Sep 24

Bullish· Aug 21

Bearish· May 7

Earnings· Feb 11

Analysts· Aug 19

Announcements· Sep 4

Technical Analysis· Feb 13

Regulars· Sep 24

Newcomers· Nov 13

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

TD Cowen reiterates Senseonics stock rating on growth drivers

Update: Beta Bionics, Senseonics to Integrate Diabetes Devices; Shares Rise

Beta Bionics, Senseonics Partner to Integrate Diabetes Devices

Beta Bionics partners with Senseonics on glucose monitoring

TD Cowen reiterates Senseonics stock rating on growth drivers

Also Discussed

Senseonics Holdings, Inc.

Company Information

Location

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

TD Cowen reiterates Senseonics stock rating on growth drivers

Update: Beta Bionics, Senseonics to Integrate Diabetes Devices; Shares Rise

Beta Bionics, Senseonics Partner to Integrate Diabetes Devices

Beta Bionics partners with Senseonics on glucose monitoring

TD Cowen reiterates Senseonics stock rating on growth drivers

Also Discussed

Social

Sep 24

Bullish· Aug 21

Bearish· May 7

Earnings· Feb 11

Analysts· Aug 19

Announcements· Sep 4

Technical Analysis· Feb 13

Regulars· Sep 24

Newcomers· Nov 13